Literature DB >> 33711414

Therapeutic applications of the cancer immunoediting hypothesis.

Rupen Desai1, Andrew T Coxon1, Gavin P Dunn2.   

Abstract

Since the late 19th century, the immune system has increasingly garnered interest as a novel avenue for cancer therapy, particularly given scientific breakthroughs in recent decades delineating the fundamental role of the immune system in tumorigenesis. The immunoediting hypothesis has articulated this role, describing three phases of the tumor-immune system interaction: Elimination, Equilibrium, and Escape wherein tumors progress from active immunologic surveillance and destruction through dynamic immunologic stasis to unfettered growth. The primary goals of immunotherapy are to restrict and revert progression through these phases, thereby improving the immune system's ability to control tumor growth. In this review, we detail the development and foundation of the cancer immunoediting hypothesis and apply this hypothesis to the dynamic immunotherapy field that includes checkpoint blockade, vaccine therapy, and adoptive cell transfer.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer immunoediting; Immunogenomics; Immunotherapy

Mesh:

Year:  2021        PMID: 33711414     DOI: 10.1016/j.semcancer.2021.03.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  3 in total

Review 1.  Exosomes in cancer immunoediting and immunotherapy.

Authors:  Yarong Zhao; Luotong Liu; Rongze Sun; Guilin Cui; Shuyu Guo; Songren Han; Ziwei Li; Tian Bai; Lesheng Teng
Journal:  Asian J Pharm Sci       Date:  2022-01-04       Impact factor: 9.273

2.  Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes.

Authors:  Zhi-Yong Shi; Sheng-Xiao Zhang; Cai-Hong Li; Di Fan; Yan Xue; Zhe-Hao Cheng; Li-Xiang Wu; Ke-Yi Lu; Zhi-Fang Wu; Xiao-Feng Li; Hai-Yan Liu; Si-Jin Li
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

Review 3.  Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy.

Authors:  Houhui Shi; Kai Li; Yanghong Ni; Xiao Liang; Xia Zhao
Journal:  Front Cell Dev Biol       Date:  2021-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.